CryoLife (NYSE:CRY) will report earnings before markets open on Thursday, July 25th. CryoLife, Inc. cryopreserves viable human tissues for cardiovascular, vascular, and orthopedic transplant applications. The Company develops and commercializes additional implantable products and single-use medical devices. CryoLife develops bioprosthetic cardiovascular devices, including novel design stentless porcine heart valves marketed in Europe.
Here is your Cheat Sheet to Cryolife Earnings:
Earnings Expectations: Analysts expect earnings of $0.07 per share on revenues of $35.45 million. Currently, the company’s P/E ratio stands at 23.27.
Analysts have a neutral outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings is a profit of $0.06 and has not changed. For the current year, the average estimate is a profit of $0.28, which is better than the estimate ninety days ago.
Here’s how Cryolife has been performing on an annual basis:
|Revenue ($) in millions||105||112||117||120||132|
|Diluted EPS ($)||1.16||0.31||0.14||0.26||0.28|
Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:
|Quarter||Jun. 30, 2012||Sep. 30, 2012||Dec. 31, 2012||Mar. 31, 2013|
|Revenue ($) in millions||33.19||33.43||32.80||35.54|
|Diluted EPS ($)||0.12||0.06||0.07||0.08|
Cryolife has beat analyst estimates 4 times in the past four quarters. Shareholders could expect a boost if the company beats estimates.
“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)